Abstract:BackgroundNeuroblastoma (NB) is the most common pediatric solid tumor that originates from neural crest-derived sympathoadrenal precursor cells that are committed to development of sympathetic nervous system. The well differentiated histological phenotype of NB tumor cells has been reportedly associated with favorable patient outcome. Retinoic acid (RA) can effectively induce NB cell differentiation, thereby being used in the clinic as a treatment agent for inducing the differentiation of high-risk NB. However, the underlying molecular mechanisms of regulating differentiation remain elusive.MethodsThe correlation between clinical characteristics, survival and the deubiquitinating enzyme ubiquitin C-terminal hydrolase 1 (UCHL1) expression were assessed using a neuroblastic tumor tissue microarray, and then validated in three independent patient datasets. The different expression of UCHL1 in ganglioneuroblastoma, ganglioneuroma and NB was detected by immunohistochemistry, mass spectra and immunoblotting analysis, and the correlation between UCHL1 expression and the differentiated histology was analyzed, which was also validated in three independent patient datasets. Furthermore, the roles of UCHL1 in NB cell differentiation and proliferation and the underlying mechanisms were studied by using short hairpin RNA and its inhibitor LDN57444 in vitro.ResultsBased on our neuroblastic tumor tissue microarrays and three independent validation datasets (Oberthuer, Versteeg and Seeger), we identified that UCHL1 served as a prognostic marker for better clinical outcome in NB. We further demonstrated that high UCHL1 expression was associated with NB differentiation, indicated by higher UCHL1 expression in ganglioneuroblastomas/ganglioneuromas and well-differentiated NB than poorly differentiated NB, and the positive correlation between UCHL1 and differentiation markers. As expected, inhibiting UCHL1 by knockdown or LDN57444 could significantly inhibit RA-induced neural differentiation of NB tumor cells, characterized by decreased neurite outgrowth and neural differentiation markers. This effect of UCHL1 was associated with positively regulating RA-induced AKT and ERK1/2 signaling activation. What's more, knockdown of UCHL1 conferred resistance to RA-induced growth arrest.ConclusionOur findings identify a pivotal role of UCHL1 in NB cell differentiation and as a prognostic marker for survival in patients with NB, potentially providing a novel therapeutic target for NB.

EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications

Downregulation of MEG3 and Upregulation of EZH2 Cooperatively Promote Neuroblastoma Progression.

Determination of Long Non-Coding RNAs Associated with EZH2 in Neuroblastoma by RIP-seq, RNA-seq and ChIP-seq

MIR-10A-Mediated RYBP Inhibition Leads to Epigenetic Overexpression of Anti-Apoptotic Protein BCL2 in Myelodysplastic Syndromes

Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma

Smoothened-Independent Activation of Hedgehog Signaling by Rearranged During Transfection Promotes Neuroblastoma Cell Proliferation and Tumor Growth

L3MBTL2 maintains MYCN-amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes

Unfavorable Neuroblastoma Prognostic Factor NLRR2 Inhibits Cell Differentiation by Transcriptional Induction Through JNK Pathway.

Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma

EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation

Ezh2 Regulates Differentiation and Function of Natural Killer Cells Through Histone Methyltransferase Activity.

Targeting TRIM24 Promotes Neuroblastoma Differentiation and Decreases Tumorigenicity Via LSD1/CoREST Complex.

METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma

Krüppel‐like Factor 9 Promotes Neuroblastoma Differentiation Via Targeting the Sonic Hedgehog Signaling Pathway

Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma

Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.

NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma.

The Deubiquitinating Enzyme UCHL1 is a Favorable Prognostic Marker in Neuroblastoma As It Promotes Neuronal Differentiation

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

Rho GTPases signaling mediates aggressiveness and differentiation in neuroblastoma tumors

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes